{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:51Z","timestamp":1792785051607,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Institutional Research Fund of University Hospital Pilsen","award":["FN 00669806"],"award-info":[{"award-number":["FN 00669806"]}]},{"name":"Charles University","award":["Cooperatio No. 43\u2014Surgical Disciplines"],"award-info":[{"award-number":["Cooperatio No. 43\u2014Surgical Disciplines"]}],"id":[{"id":"https:\/\/ror.org\/024d6js02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60731-3","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T13:44:19Z","timestamp":1783259059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early systemic inflammatory\u2013metabolic trajectory phenotypes are associated with survival outcomes in metastatic renal cell carcinoma treated with nivolumab"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-7385","authenticated-orcid":false,"given":"Ond\u0159ej","family":"Fiala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Poprach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Kopeck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Obertov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vo\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mat\u011bj\u016f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane\u017eka","family":"Zem\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Spisarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Tkadlecov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Priester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Lohynsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Grmelov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Hrn\u010d\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"\u017d\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Chovanec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kr\u00e1l\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katar\u00edna","family":"Rejlekov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Str\u00e1nsk\u00fd Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Palacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,5]]},"reference":[{"issue":"19","key":"60731_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl. J. Med. 373 (19), 1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665 (2015).","journal-title":"N Engl. J. Med."},{"issue":"14","key":"60731_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl. J. Med. 378 (14), 1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126 (2018).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"60731_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex, A. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. Eur. Urol. 87 (6), 683\u2013696 (2025). Epub 2025 Mar 20. PMID: 40118739.","journal-title":"Eur. Urol."},{"issue":"8","key":"60731_CR4","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17 (8), 2530\u20132540. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2530 (1999).","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"60731_CR5","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DYC Heng","year":"2009","unstructured":"Heng, D. Y. C. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27 (34), 5794\u20135799 (2009).","journal-title":"J. Clin. Oncol."},{"key":"60731_CR6","unstructured":"Yip, S. M. et al. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer."},{"key":"60731_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijsu.2020.05.019","volume":"79","author":"N Zhang","year":"2020","unstructured":"Zhang, N. et al. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis. Int. J. Surg. 79, 66\u201373 (2020). Epub 2020 May 14. PMID: 32417461.","journal-title":"Int. J. Surg."},{"key":"60731_CR8","doi-asserted-by":"publisher","first-page":"746976","DOI":"10.3389\/fonc.2021.746976","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen, X., Meng, F. & Jiang, R. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol. 11, 746976. https:\/\/doi.org\/10.3389\/fonc.2021.746976 (2021). PMID: 34900692; PMCID: PMC8660071.","journal-title":"Front. Oncol."},{"issue":"2","key":"60731_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.clgc.2023.11.013","volume":"22","author":"FSM Monteiro","year":"2024","unstructured":"Monteiro, F. S. M. et al. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study. Clin. Genitourin. Cancer. 22 (2), 305\u2013314e3 (2024). Epub 2023 Nov 24. PMID: 38087702.","journal-title":"Clin. Genitourin. Cancer"},{"key":"60731_CR10","doi-asserted-by":"crossref","unstructured":"Zhou, X. & Luo, G. A meta-analysis of the platelet-lymphocyte ratio: A notable prognostic factor in renal cell carcinoma. Int J Biol Markers. ;37(2):123\u2013133. doi: 10.1177\/03936155221081536. Epub 2022 Mar 3. PMID: 35238678. (2022).","DOI":"10.1177\/03936155221081536"},{"issue":"9","key":"60731_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2217\/imt-2021-0207","volume":"14","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa, T. et al. Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 14 (9), 709\u2013725. https:\/\/doi.org\/10.2217\/imt-2021-0207 (2022). Epub 2022 Apr 25. PMID: 35465726.","journal-title":"Immunotherapy"},{"key":"60731_CR12","doi-asserted-by":"publisher","unstructured":"Rebuzzi, S. E. et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol. ;13:17588359211019642. doi: 10.1177\/17588359211019642. Erratum in: Ther Adv Med Oncol. 2021;13:17588359211036552. (2021). https:\/\/doi.org\/10.1177\/17588359211036552. PMID: 34046089; PMCID: PMC8135208.","DOI":"10.1177\/17588359211036552"},{"issue":"2","key":"60731_CR13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/curroncol28020133","volume":"28","author":"K Iinuma","year":"2021","unstructured":"Iinuma, K. et al. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. Curr. Oncol. 28 (2), 1402\u20131411. https:\/\/doi.org\/10.3390\/curroncol28020133 (2021). PMID: 33916792; PMCID: PMC8167798.","journal-title":"Curr. Oncol."},{"key":"60731_CR14","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s00262-020-02637-1","volume":"69","author":"A Simonaggio","year":"2020","unstructured":"Simonaggio, A. et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol. Immunother. 69, 2513\u20132522. https:\/\/doi.org\/10.1007\/s00262-020-02637-1 (2020).","journal-title":"Cancer Immunol. Immunother"},{"issue":"1","key":"60731_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/tjem.tjem_198_23","volume":"24","author":"MM Islam","year":"2024","unstructured":"Islam, M. M., Osoydan Satici, M. & Eroglu, S. E. Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review. Turk. J. Emerg. Med. 24 (1), 8\u201319. https:\/\/doi.org\/10.4103\/tjem.tjem_198_23 (2024).","journal-title":"Turk. J. Emerg. Med."},{"issue":"5","key":"60731_CR16","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1007\/s12032-012-0286-9","volume":"29","author":"A Poprach","year":"2012","unstructured":"Poprach, A. et al. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Med. Oncol. 29 (5), 3314\u20133320. https:\/\/doi.org\/10.1007\/s12032-012-0286-9 (2012). Epub 2012 Jun 30. PMID: 22752571.","journal-title":"Med. Oncol."},{"key":"60731_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumours. J. Natl. Cancer Inst. 92, 205\u2013216. https:\/\/doi.org\/10.1093\/jnci\/92.3.205 (2000).","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"60731_CR18","doi-asserted-by":"publisher","first-page":"25365","DOI":"10.1038\/s41598-024-76928-3","volume":"14","author":"BT Buerk","year":"2024","unstructured":"Buerk, B. T. et al. Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy. Sci. Rep. 14 (1), 25365. https:\/\/doi.org\/10.1038\/s41598-024-76928-3 (2024). PMID: 39455722; PMCID: PMC11511985.","journal-title":"Sci. Rep."},{"issue":"1","key":"60731_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4143\/crt.2017.033","volume":"50","author":"P Chrom","year":"2018","unstructured":"Chrom, P., Stec, R., Bodnar, L., Szczylik, C. & Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model. Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and. Cancer Res. Treat. 50 (1), 103\u2013110 (2018). Epub 2017 Mar 3. PMID: 28253564; PMCID: PMC5784637.","journal-title":"Cancer Res. Treat."},{"key":"60731_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","volume":"6","author":"A-K-A Lalani","year":"2018","unstructured":"Lalani, A-K-A. et al. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J. Immunother Cancer. 6, 5 (2018).","journal-title":"J. Immunother Cancer"},{"key":"60731_CR21","unstructured":"St\u00fchler, V. et al. Role of the systemic immune-inflammation index in patients treated with first-line immune combinations for metastatic renal cell carcinoma. Eur. Urol. Open. Sci. ; (2022). (article details per journal record)."},{"key":"60731_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.urolonc.2017.01.016","volume":"35","author":"R Boissier","year":"2017","unstructured":"Boissier, R., Campagna, J., Branger, N., Karsenty, G. & Lechevallier, E. The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: a review. Urol. Oncol. 35, 135\u2013141 (2017).","journal-title":"Urol. Oncol."},{"key":"60731_CR23","doi-asserted-by":"publisher","unstructured":"Nunno, V. D. et al. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy. ;11(7):631\u2013643. (2019). https:\/\/doi.org\/10.2217\/imt-2018-0175. PMID: 30943858.","DOI":"10.2217\/imt-2018-0175"},{"issue":"4","key":"60731_CR24","doi-asserted-by":"publisher","first-page":"e006404","DOI":"10.1136\/bmjopen-2014-006404","volume":"5","author":"K Hu","year":"2015","unstructured":"Hu, K., Lou, L., Ye, J. & Zhang, S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ Open. 5 (4), e006404. https:\/\/doi.org\/10.1136\/bmjopen-2014-006404 (2015). PMID: 25854964; PMCID: PMC4390726.","journal-title":"BMJ Open."},{"issue":"1","key":"60731_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cncr.31778","volume":"125","author":"MA Bilen","year":"2019","unstructured":"Bilen, M. A. et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer 125 (1), 127\u2013134. https:\/\/doi.org\/10.1002\/cncr.31778 (2019). Epub 2018 Oct 17. PMID: 30329148.","journal-title":"Cancer"},{"issue":"13","key":"60731_CR26","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-18-3661","volume":"25","author":"U De Giorgi","year":"2019","unstructured":"De Giorgi, U. et al. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clin. Cancer Res. 25 (13), 3839\u20133846. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3661 (2019). Epub 2019 Apr 9. PMID: 30967420.","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"60731_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.urolonc.2013.07.016","volume":"32","author":"Q Hu","year":"2014","unstructured":"Hu, Q. et al. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol. Oncol. 32 (1), 50 (2014). Epub 2013 Nov 13. PMID: 24239465.e1-8.","journal-title":"Urol. Oncol."},{"issue":"2","key":"60731_CR28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.juro.2009.10.014","volume":"183","author":"TV Johnson","year":"2010","unstructured":"Johnson, T. V. et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J. Urol. 183 (2), 480\u2013485. https:\/\/doi.org\/10.1016\/j.juro.2009.10.014 (2010). Epub 2009 Dec 14. PMID: 20006861.","journal-title":"J. Urol."},{"issue":"2","key":"60731_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1442-2042.2012.03121.x","volume":"20","author":"K Saito","year":"2013","unstructured":"Saito, K. & Kihara, K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int. J. Urol. 20 (2), 161\u2013171. https:\/\/doi.org\/10.1111\/j.1442-2042.2012.03121.x (2013). Epub 2012 Aug 16. PMID: 22897628.","journal-title":"Int. J. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60731-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:08:31Z","timestamp":1791158911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60731-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60731"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60731-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,5]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ond\u0159ej Fiala received honoraria from Novartis, Janssen, Merck, Ipsen, BMS, MSD, Pierre Fabre, and Pfizer for consultations and lectures unrelated to this project.Tomas Buchler has received research support: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck KGaA, MSD, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi\/Aventis; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, AstraZeneca, Roche, Servier, Accord, MSD, and Pfizer. All of the above are unrelated to the present paper.Alexandr Poprach has received consulting fees from Bristol Myers Squibb, Roche, Eisai, Astellas, Johnson & Johnson, Zentiva, Novartis, Pfizer, Merck, MSD, Ipsen; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, MSD, Merck, Novartis, Eisai, Astellas, Johnson & Johnson and Pfizer. All of the above are unrelated to the present paper.Jind\u0159ich Kopeck\u00fd has received consulting fees from Bristol Myers Squibb, Novartis, Pfizer, Merck, MSD, Ipsen; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, MSD, Merck, Novartis and Pfizer. All of the above are unrelated to the present paper.Jana Obertova has received payment for speakers\u2019 bureaus, presentations, lectures or educational events from MSD, Astellas, Bayer, and Ipsen and Janssen. All the above are unrelated to this paper.Michal Vo\u010dka has received consulting fees from Merck, Roche, MSD; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from BMS, MSD, Merck, Novartis, AstraZeneca, Roche and Pfizer. All of the above are unrelated to the present paper.Martin Mat\u011bj\u016f has received consulting fees from Novartis, MSD, Astellas; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Ipsen, BMS, MSD, Merck, Novartis, Eisa, AstraZeneca, Roche and Pfizer. All of the above are unrelated to the present paper.Radka Lohynsk\u00e1 has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Roche, Janssen, Bristol Myers Squibb, MSD and Merck. All of the above are unrelated to the present paper.Matej Hrn\u010d\u00e1r payment for speakers\u2019 bureaus, presentations, lectures or educational events unrelated to this paper from Astellas, Bayer, Bristol Myers Squibb, Janssen, Novartis, Roche, Servier, Zentiva. All above are unrelated to the present paper.Monika \u017d\u00e1k has received payment for speakers\u2019 bureaus, lectures and presentations from Eli Lilly, Janssen, Novartis and Zentiva. All above are unrelated to the present paper.Michal Chovanec has received payment for speakers\u2019 bureaus, lectures and presentations, consulting fees, and educational events from Bayer, Bristol Myers Squibb, Janssen, Merck, Novartis, Teva and Zentiva. All above are unrelated to the present paper.Katarina Rejlekova has received payment for speakers\u2019 bureaus, presentations, lectures or educational events from Bayer, Novartis, Ipsen, Merck and Pfizer. All the above are unrelated to this paper.Bohuslav Melichar received honoraria from Novartis, Pfizer, Bayer-Schering, Astellas, and Roche for lectures and advisory boards unrelated to this project.Patrik Palacka has received consulting fees from Bristol Myers Squibb, Astellas, Pfizer and Merck; payment for speakers\u2019 bureaus, presentations, lectures or educational events from Bayer, MSD, Novartis, Ipsen, Janssen, Bristol Myers Squibb, Merck, Astellas and Pfizer. All the above are unrelated to this paper.Hana \u0160tudentov\u00e1 has received consulting fees from Bristol Myers Squibb, MSD, Ipsen, Novartis, Astellas and Janssen; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, or educational events from Ipsen, Merck, Bristol Myers Squibb, Novartis, MSD, and Pfizer. All of the above are unrelated to the present paper.All other authors have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the study protocol, the ethical principles stated in the Declaration of Helsinki as well as those indicated in the International Conference on Harmonization (ICH) Note for Guidance on Good Clinical Practice (GCP; ICH E6, 1995), and all applicable regulatory requirements. RENIS II registry was approved by the Ethics Committee of the Masaryk Memorial Cancer Institute, Brno, Czech Republic. All patients provided informed consent. For deceased or untraceable individuals, the Institutional Review Board of the coordinating center waived the requirement for consent.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30811"}}